News | November 28, 2025
GV20 Therapeutics hits milestone in AI-driven cancer therapy collaboration with Mitsubishi Tanabe Pharma
GV20 received an upfront payment and is eligible for additional milestone payments
GV20 received an upfront payment and is eligible for additional milestone payments
The drug, intended for chronic weight management alongside diet and exercise, is now under the FDA’s new CNPV expedited review pathway
The State’s PPP model has already mobilised Rs. 150 crore in core infrastructure, while Thermo Fisher has invested Rs. 90 crore in the Bioprocess Design Centre and its co-located Customer Experience Centre
Topline results from the Phase 2 VISTA trial show that PIPE-307 did not meet its primary or secondary efficacy endpoints
The non-dilutive financing includes three tranches
The licence covers Actimed’s existing patents, its proprietary know-how and any future related patents, giving Mankind full control to advance the products under its own brands
The patent will lock in broad protection for the company’s lead therapy CardiolRx and its novel subcutaneous candidate CRD-38
Both companies will jointly execute development and scale-up of multiple strategic APIs, including late-stage NCE-1 opportunities
Stivarga is the standard third-line treatment for metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma
This strategic initiative aims to accelerate proof-of-concept of pipeline assets by streamlining R&D operations
Subscribe To Our Newsletter & Stay Updated
